IRIDEX Corporation, Inc. (NASDAQ:IRIX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Trip Taylor - IR Patrick Mercer - CEO, President & Director Romeo Dizon - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
IRIDEX's strategic review ended without a major asset sale, but a $10M investment from Novel Inspiration International offers growth potential and cash stability. Novel's investment values IRIDEX shares at $2.00/share, significantly higher than current trading prices, indicating a belief in the company's undervaluation. The recent LCD change in glaucoma treatment reimbursement could significantly boost IRIDEX's glaucoma business, potentially increasing the company's market valuation.
IRIDEX Corporation (NASDAQ:IRIX ) Strategic Vision Conference Call April 16, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Patrick Mercer - Chief Executive Officer Will Moore - Board of Directors Conference Call Participants Aaron Warwick - Breakout Investors Jason Stankowski - Clayton Partners Mark Gomes - Pipeline Data Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
IRIDEX Corporation (NASDAQ:IRIX ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Department Patrick Mercer - Chief Executive Officer Romeo Dizon - Chief Financial Officer Conference Call Participants Operator Hello. And welcome to the Fourth Quarter 2024 IRIDEX Earnings Conference Call.
IRIDEX Corporation (NASDAQ:IRIX ) Q3 2024 Earnings Call Transcript November 12, 2024 5:00 PM ET Company Participants Scott Shuda - Executive Chairman Patrick Mercer - CEO Fuad Ahmad - Interim CFO Operator Thank you all for participating in today's call. Joining me from the company are Scott Shuda, Executive Chairman; Patrick Mercer, Chief Executive Officer; and Fuad Ahmad, Interim Chief Financial Officer.
IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all assets and has taken steps to ensure financial sustainability during the process. The CEO expects agreements for the sale of assets by the end of 2024, potentially doubling the current share price within the next 3-6 months.
IRIDEX Corporation (NASDAQ:IRIX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Good day, and thank you for standing by. At this time I would like to welcome everyone to IRIDEX Second Quarter 2024 Earnings Conference Call.
Iridex (IRIX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
IRIDEX Corporation (NASDAQ:IRIX ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to Q1 2024 IRIDEX Earnings Conference Call.